- Home
- EML vs ATOS Comparison
EML vs ATOS Comparison
Compare EML & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- ATOS
- Stock Information
- Founded
- EML 1858
- ATOS 2009
- Country
- EML United States
- ATOS United States
- Employees
- EML N/A
- ATOS N/A
- Industry
- EML Industrial Machinery/Components
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- ATOS Health Care
- Exchange
- EML Nasdaq
- ATOS Nasdaq
- Market Cap
- EML 191.3M
- ATOS 140.9M
- IPO Year
- EML N/A
- ATOS 2012
- Fundamental
- Price
- EML $27.77
- ATOS $0.96
- Analyst Decision
- EML
- ATOS Strong Buy
- Analyst Count
- EML 0
- ATOS 3
- Target Price
- EML N/A
- ATOS $7.00
- AVG Volume (30 Days)
- EML 16.1K
- ATOS 942.6K
- Earning Date
- EML 11-01-2024
- ATOS 11-12-2024
- Dividend Yield
- EML 1.58%
- ATOS N/A
- EPS Growth
- EML N/A
- ATOS N/A
- EPS
- EML N/A
- ATOS N/A
- Revenue
- EML $284,461,286.00
- ATOS N/A
- Revenue This Year
- EML N/A
- ATOS N/A
- Revenue Next Year
- EML N/A
- ATOS N/A
- P/E Ratio
- EML $13.94
- ATOS N/A
- Revenue Growth
- EML 7.70
- ATOS N/A
- 52 Week Low
- EML $20.50
- ATOS $0.73
- 52 Week High
- EML $35.78
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- EML 40.52
- ATOS 24.57
- Support Level
- EML $28.21
- ATOS $1.17
- Resistance Level
- EML $30.72
- ATOS $1.30
- Average True Range (ATR)
- EML 1.10
- ATOS 0.08
- MACD
- EML -0.08
- ATOS -0.02
- Stochastic Oscillator
- EML 0.00
- ATOS 1.09
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.